Special Section on Medicines Development in China Focus on China

International Journal of Pharmaceutical Medicine

, Volume 20, Issue 6, pp 355-359

First online:

China as a Growing Research Base for Innovation in Medicines Development

  • Michael HumphriesAffiliated withNovartis China Email author 
  • , Detlef NieseAffiliated withNovartis Pharma A.G.
  • , Paul DaiAffiliated withNovartis China

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


In the current context of China’s rapidly growing economy, multinational drug companies are investing significantly in research and development in China, a trend that has accelerated over the last 10 years. A robust regulatory framework, an abundance of highly equipped medical universities and large patient numbers in all therapy areas make China an increasingly attractive location to conduct clinical research. In addition, data from China are now accepted for inclusion in applications for market authorisation by regulatory agencies worldwide, including the Food and Drug Administration (FDA) in the US. Hence China is becoming an equal partner in global clinical development, a trend that is likely to grow significantly in the years to come.